Adults with immunoglobulin A nephropathy (IgAN) who keep leaking protein into their urine despite standard care have a new treatment option aimed at the immune pathway driving the damage. On 21 October 2026, AstraZeneca announced that the U.S. Food and Drug Administration (FDA) has approved Ultomiris (ravulizumab), developed by Alexion, AstraZeneca's rare disease unit, to reduce proteinuria in adults with primary IgAN at risk of disease progression. The approval, granted under the FDA's accelerated approval pathway after Priority Review, makes Ultomiris the first and only C5 complement inhibitor approved for this use, and it rests on an interim result: a 43.4% reduction in proteinuria compared with placebo at 34 weeks in the I CAN phase III trial.
What the FDA Approved
The approved indication is specific: reduction of proteinuria in adults with primary IgAN who are at risk of disease progression. IgAN is a rare, inflammatory kidney disease in which abnormal IgA proteins form immune complexes that lodge in the kidneys and activate the complement system, driving inflammation that damages the glomeruli, the kidney's filtering units, and can progress to chronic kidney disease and end-stage kidney disease. Ultomiris works by inhibiting the C5 protein in the terminal complement cascade, providing immediate, complete and sustained complement inhibition. After a loading dose it is administered intravenously every eight weeks in adults, on a weight-based schedule. Two qualifications in the announcement matter for how the drug should be described. First, the approval is an accelerated approval based on the proteinuria endpoint. Second, AstraZeneca states plainly that it has not been established whether Ultomiris slows kidney function decline in IgAN, and that continued approval for this indication may be contingent on verification of clinical benefit in the still-running I CAN trial. This is the fifth approved indication for Ultomiris, which is already used in several other complement-mediated rare diseases.
What the I CAN Trial Showed
I CAN is a global, randomised, double-blind, placebo-controlled phase III trial in adults with IgAN at risk of progression, designed to enrol approximately 510 participants across 28 countries, all on stable standard-of-care treatment for at least three months before screening. In the prespecified interim analysis, 24-hour urine protein creatinine ratio (UPCR) fell 46.6% from baseline at week 34 on Ultomiris, versus 5.6% on placebo, a placebo-adjusted treatment effect of 43.4% (95% confidence interval 33.5% to 51.8%; p<0.0001). The reduction appeared early, at 36.7% by week 10, and was sustained through week 34, consistently across demographic and disease-severity subgroups. The trial continues to its final primary endpoint, change in estimated glomerular filtration rate (eGFR) at week 106, which is intended to support traditional approval. Late-breaking interim results are being presented at the American Society of Nephrology's Kidney Week 2026. On safety, the interim profile was consistent with the known profile of Ultomiris and generally well tolerated, with no new safety concerns: the most common adverse events on treatment were upper respiratory tract infection (11.3%), nasopharyngitis (9.2%) and infusion-related reactions (8.4%). Regulatory submissions based on the interim results are also under review in Japan and other countries.
What This Means for Nephrology Practices
For nephrology practices and infusion services, this approval creates a defined, recurring workflow rather than a one-off prescription. Eligible patients are those with primary IgAN, persistent proteinuria and risk of progression on standard care, so practices need UPCR results tracked longitudinally and visibly in the chart to identify candidates and to evidence response after treatment starts. The every-eight-week intravenous schedule, following a loading dose, means infusion capacity, authorisation for a high-cost rare-disease therapy, and reminder and follow-up systems that hold patients on a two-month cycle for an extended period (see https://medclinicx.com/solutions/ai-patient-portal). Counselling needs to be precise, because the accelerated-approval basis is easy to overstate: the drug is proven to reduce proteinuria, a marker strongly associated with progression, but it is not yet proven to slow the loss of kidney function itself. Patients should hear that distinction from their care team, not discover it later. The population is not small for a rare disease: AstraZeneca cites more than 200,000 people living with IgAN in the US, with roughly half of those who have raised urine protein or reduced kidney function at high risk of kidney failure within 10 years of diagnosis. This article is general information about a regulatory decision, not medical advice for any individual patient.
Analysis: A Surrogate Endpoint, Deliberately Labelled
Analysis (MedClinicX): This is accelerated approval working as designed, and the announcement is unusually clear about it. Proteinuria reduction is an accepted surrogate in IgAN because persistent proteinuria signals ongoing kidney injury, but the outcome patients and payers ultimately care about, preserved kidney function, will not be known until the week-106 eGFR readout. Clinics adopting Ultomiris early are therefore also adopting a measurement obligation: baseline and follow-up UPCR and eGFR, recorded consistently, are what will show whether the surrogate benefit is translating in their own population, and they are the data payers will ask for when the traditional-approval decision lands. AstraZeneca's parallel move with Oracle on AI-supported clinical trial matching, covered earlier this week (https://medclinicx.com/news/oracle-astrazeneca-ai-clinical-trials-partnership), underlines the same pattern across the company: complement and data infrastructure first, outcomes proof on a published timetable.
Sources and References
- AstraZeneca (Alexion), Ultomiris received accelerated approval in the US as first and only C5 complement inhibitor to reduce proteinuria in adults with primary immunoglobulin A nephropathy, 21 October 2026: https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2026/ultomiris-approved-in-us-in-igan.html
- Reuters, AstraZeneca says FDA approves drug for rare kidney disease in adults, 21 October 2026: https://www.reuters.com/business/healthcare-pharmaceuticals/astrazeneca-says-fda-approves-drug-rare-kidney-disease-adults-2026-10-21/
Reporting based on the sources above, accessed 22 October 2026. The AstraZeneca announcement was read directly in full, and the Reuters report was cross-checked against it. All trial figures, dates and eligibility details in this article come from the announcement. MedClinicX did not conduct original reporting or interviews for this article. Corrections: contact us via https://medclinicx.com/contact